ERBB2 and breast cancer: In particular, the presence of CD8+ cells in the tumor prior to the onset of neoadjuvant chemotherapy has been shown to predict response to therapy including pathological complete response particularly in triple-negative and HER2-expressing breast cancers [47,48,49,50].